In this issue:
- Impact of DMTs on COVID-19 risk in pwMS
- Use of DMTs in pregnancy
- Critical spinal cord lesions and secondary progressive motor impairment
- Prediction of on-treatment disability worsening in RRMS
- Functional electrical stimulation for foot drop in pwMS
- Real-world efficacy of natalizumab in patients with RRMS
- Disability outcomes in patients with early cerebellar or brainstem symptoms
- Breastfeeding and MS treatments
- Discontinuing cannabis may improve depression in pwMS
- Defining the course of tumefactive MS
Please login below to download this issue (PDF)